Form 8-K

8-K — Orchestra BioMed Holdings, Inc.

Accession: 0001104659-26-112586

Filed: 2026-10-01

Period: 2026-10-01

CIK: 0001814114

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2626728d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2626728d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2626728d1_8k.htm · Sequence: 1

false

0001814114

2026-10-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13

OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 1, 2026

ORCHESTRA BIOMED

HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation)

001-39421

(Commission

File Number)

92-2038755

(IRS Employer

Identification No.)

150 Union Square Drive

New Hope, Pennsylvania 18938

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (215) 862-5797

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each

class

Trading Symbol(s)

Name of each

exchange on which

registered

Common stock, par value $0.0001 per share

OBIO

The Nasdaq Global Market

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 7.01.

Regulation FD Disclosure.

On October 1, 2026, Orchestra

BioMed Holdings, Inc. (the “Company”) issued a press release titled “Orchestra BioMed Exceeds Enrollment Target in the

BACKBEAT Global Pivotal Trial of AVIM Therapy.” A copy of the press release is attached to this Current Report on Form 8-K (“Current

Report”) as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure.

The information in Item

7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for

purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by

reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference

language in any such filing.

Item 8.01.

Other Events.

On October 1, 2026, the

Company announced that, as of September 30, 2026, 330 patients had been randomized in the BACKBEAT

Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced target of 316 randomized patients. The BACKBEAT

Trial is evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in pacemaker-indicated patients with uncontrolled

hypertension despite the use of medication. The BACKBEAT Trial is being conducted with Medtronic plc (NYSE: MDT), the Company’s

strategic collaborator for the BACKBEAT Trial and, subject to regulatory approval, for the commercialization of AVIM Therapy in pacemaker-indicated

patients with uncontrolled hypertension despite the use of medication. The 330 patients enrolled in the BACKBEAT Trial have been randomized

at 81 sites across 13 countries. The BACKBEAT Trial’s protocol, approved by the U.S. Food and Drug Administration, specifies 284

evaluable randomized subjects for the primary endpoint analysis, with a total enrollment target of 316 patients to account for potential

loss to follow-up.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release, dated as of October 1, 2026.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORCHESTRA BIOMED HOLDINGS, INC.

By:

/s/ Andrew Taylor

Name:

Andrew Taylor

Title:

Chief Financial Officer

Date: October 1, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2626728d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Orchestra BioMed Exceeds Full Enrollment Target

in the BACKBEAT Global Pivotal Trial of AVIM Therapy

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target

Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027

Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

NEW HOPE, Pa., Oct. 1, 2026 (GLOBE NEWSWIRE)

— Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company

accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced

that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced

target of 316 randomized patients. The BACKBEAT Trial is evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”)

in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication. Hypertension is the most common modifiable

risk factor for death worldwide and the most common comorbidity among the pacemaker population.1

The BACKBEAT Trial (NCT06059638) is being conducted

with Medtronic plc (NYSE: MDT, “Medtronic”), the Company's strategic collaborator for the BACKBEAT Trial and, subject to regulatory

approval, for the commercialization of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of

medication.

As of September 30, 2026, 330 patients have been randomized in the BACKBEAT Trial at 81 sites across 13 countries.

The BACKBEAT Trial’s protocol, approved by the U.S. Food and Drug Administration (the “FDA”), specifies 284 evaluable randomized subjects for the primary endpoint analysis, with a total enrollment target of 316 patients to account for potential loss to follow-up.

The BACKBEAT Trial is a global, multi-center,

prospective, randomized, double-blind pivotal trial. Patients are randomized 1:1 to AVIM Therapy combined with continued medical therapy

and pacing (treatment) or continued medical therapy and standard pacing alone (control). The primary efficacy endpoint of the BACKBEAT

Trial is the between-group difference in the change in 24-hour ambulatory systolic blood pressure (“aSBP”) at three-month

follow-up from pre-randomization baseline. The primary safety endpoint is freedom from unanticipated serious adverse device events in

the AVIM Therapy arm at three-month follow-up. The protocol-specified sample size provides greater than 90% statistical power for both

primary endpoints and is designed to detect a between-group difference of at least 5 mmHg in aSBP.

David Hochman, Chairman & Chief Executive

Officer of Orchestra BioMed, commented, “Achieving and surpassing full enrollment of the BACKBEAT Trial is a defining milestone

for Orchestra BioMed, for our collaboration with Medtronic and potentially for the millions of high cardiovascular risk patients who remain

above blood pressure target despite the medications available to them today. We are grateful for and excited about the enrollment momentum

built across our global trial site network over the last year. I want to thank the patients and their families who chose to participate,

and the clinical teams and investigators at our trial sites globally whose commitment made this milestone possible. Our focus now turns

to completing three-month follow-up, database lock, and the delivery of a rigorous, well-powered data set next spring.”

1 World Health Organization,

Global Report on Hypertension 2025 (an estimated 1.4B adults aged 30–79 with hypertension in 2024, 33% of that age group; ~23% of

those living with hypertension have their blood pressure effectively controlled).

Robert C. Kowal, M.D., Ph.D., Vice President

and General Manager for Cardiac Pacing Therapies in the Medtronic Electrophysiology Therapies operating unit, stated, “For decades,

cardiac pacing has been foundational in the management of rhythm disorders. Reaching full enrollment in the BACKBEAT Trial brings us a

big step closer to understanding whether AVIM Therapy can extend the role of cardiac pacing therapy to include hypertension management

for patients at increased cardiovascular risk. We are proud of the collaborative work our team and Orchestra BioMed’s team have

done alongside investigators around the world, and we look forward to the primary endpoint results.”

Vivek Reddy, M.D., Executive Chairman of the

BACKBEAT Clinical Steering Committee, Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital and Director of

Electrophysiology for the Mount Sinai Health System, commented, “Randomized, double-blind evidence is the highest standard by

which a new therapeutic modality earns its place in clinical practice, and that is exactly what the BACKBEAT Trial was designed to generate.

The pilot data for AVIM Therapy have been exciting, consistent and mechanistically coherent, but the field needs a pivotal trial to answer

the question definitively. On behalf of the Steering Committee, I want to recognize the investigators, coordinators and other professionals

whose work enabled the trial to reach full enrollment, and I look forward to seeing the three-month primary endpoint results.”

Clinical, Regulatory and Commercial Next Steps

Orchestra BioMed and Medtronic intend to submit

the BACKBEAT Trial’s primary endpoint results for consideration as a late-breaking clinical trial presentation at a major cardiovascular

conference in the second quarter of 2027. Assuming positive results from the BACKBEAT Trial, Medtronic plans to submit AVIM Therapy marketing

applications to the FDA and other global regulatory agencies promptly.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company

accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies.

The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion

Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar

annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide,

and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients

with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies

in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment

of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients,

as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular

risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver

a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic

artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for

the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further

information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible

with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot

studies in patients with hypertension who are also indicated for a pacemaker. In MODERATO II, a double-blind, randomized pilot study,

AVIM Therapy-treated patients had a mean reduction of 11.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) from pre-randomization

baseline at six months, representing a net reduction of 8.1 mmHg versus control patients. At the same time point, the net reduction in

office systolic blood pressure (oSBP) was 12.3 mmHg versus control.

Additional MODERATO II data showed an immediate

mean oSBP reduction of 13.2 mmHg when AVIM Therapy was activated during setup before randomization, with 97% of patients achieving a reduction

of at least 5 mmHg. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function

and hemodynamics.

The BACKBEAT (BradycArdia paCemaKer with atrioventricular

interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering

blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for

or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the

FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements

Certain statements included in this press release

that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private

Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,”

“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”

“expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,”

“seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends

or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating

to the timing, implementation, results and design of the Company’s ongoing pivotal trials, the timing of regulatory submissions,

realizing the clinical and commercial value of the Company’s product candidates, the potential safety and efficacy of the Company’s

product candidates, the size of the potential markets for the Company’s product candidates, and the ability of the Company’s

partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this

press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These

forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a

guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult

or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business,

market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates

and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve

expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed

under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, which was filed with the SEC on March 12, 2026.

The Company operates in a very competitive

and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against

placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not

plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact:

Silas Newcomb

Orchestra BioMed

snewcomb@orchestrabiomed.com

Media Contact:

Nina Premutico

Orchestra BioMed

npremutico@orchestrabiomed.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 01, 2026

Entity File Number

001-39421

Entity Registrant Name

ORCHESTRA BIOMED

HOLDINGS, INC.

Entity Central Index Key

0001814114

Entity Tax Identification Number

92-2038755

Entity Incorporation, State or Country Code

Entity Address, Address Line One

150 Union Square Drive

Entity Address, City or Town

New Hope

Entity Address, State or Province

Entity Address, Postal Zip Code

18938

City Area Code

215

Local Phone Number

862-5797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.0001 per share

Trading Symbol

OBIO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration